Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lundbeck's New Partnering Focus: Link Up With Genmab On Research And Merck On Marketing Sycrest

This article was originally published in The Pink Sheet Daily

Executive Summary

Lundbeck to collaborate on CNS research with fellow Danish firm Genmab, and to exclusively market Merck's antipsychotic Sycrest outside the U.S., China and Japan.

You may also be interested in...



Deals Of The Week: Sanofi/TargeGen, Arena/Eisai, GSK/Genmab ...

Each week, "The Pink Sheet" presents commentary on some of the week's most interesting business deals, contributed by the editors of the IN VIVO blog. Visit the blog at 1http://invivoblog.blogspot.com/.

Lundbeck Defends Its Escitalopram Patent In Denmark, But Not In Spain

Lundbeck's top-selling product, Cipralex, is responsible for more than half its sales, but faces generic competition in Spain.

Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind

Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.

Topics

UsernamePublicRestriction

Register

PS071302

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel